New HPV Screening Set to Transform Cervical Cancer Detection in Quebec

A new cervical cancer screening initiative is set to launch in Quebec, providing enhanced detection options for women. This development comes in the wake of a shift from traditional pap tests to more advanced HPV testing methods that promise higher sensitivity and accuracy. The initiative is particularly significant for women like Jennifer Curran, who received a cervical cancer diagnosis during her pregnancy.

Curran, now 44, had no prior symptoms when she learned about her cancer diagnosis. She underwent surgery to remove the cancer during her cesarean section. Despite her ordeal, Curran emphasized the importance of focusing on her newborn, stating, “I didn’t get a chance to linger in being sad for myself because I had this little baby to take care of.” Unfortunately, the HPV vaccine was not available during her school years, which is a critical tool in preventing cervical cancer linked to the HPV virus.

According to the Canadian Cancer Society, approximately 430 Canadians die from cervical cancer annually, with most cases occurring in women under 50. Traditionally, pap tests have been the main detection method, but ongoing research is pivoting towards HPV tests, which can identify the virus before it leads to abnormal cell changes.

Dr. Annie Leung, a gynecologic oncologist at the McGill University Health Centre (MUHC), leads a team working on a new HPV screening project. She noted that the ability to detect HPV before it causes abnormal cell changes could spare women from invasive treatments, including the removal of the uterus and cervix. “The possibility that I would need to do surgery to remove their uterus and cervix has huge implications on what their future looks like,” Dr. Leung explained.

While pap tests will still be recommended, the introduction of self-testing kits—allowing women to conduct swabs at home—aims to make screening more accessible. This approach is particularly vital in northern and Indigenous communities, where cervical cancer rates are among the highest in Canada. “With new technology, we’re able to actually detect the virus itself,” Dr. Leung said. “So before we even see abnormal cells, we are able to identify and detect the virus that causes the abnormal cells.”

Self-screening is already available in British Columbia and Ontario, with plans for rollout in Quebec expected by mid-2026. The MUHC Foundation is funding Dr. Leung’s research and has committed to raising $5 million for research into women’s diseases, which have historically received limited funding. Kim Cavener, who leads strategic giving at the foundation, noted, “Women’s health research receives only 7 percent of federal health research funding in Canada.”

Curran is collaborating with the MUHC Foundation to raise awareness and funds for cervical cancer research. She hopes her personal story will encourage others to seek HPV testing. “Had I had that test available to me at the time, my story could have been very, very different,” she reflected.

Fortunately, her journey has a positive outcome; her daughter is approaching her fifth birthday, and both mother and child are thriving. The new screening initiative represents not just a medical advancement, but a significant step towards better health outcomes for women across Quebec.